Malaria Infections and Infestations Malaria
Conditions
Interventions
Sulphadoxine-pyrimethamine or placebo given at EPI visits DPT2, DPT3 and measles. Collection of sera to establish impact (if any) upon EPI antigens.
Sponsors
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Infants of both gender whose parents or guardians give consent and agree to participate in the study for at least eighteen months 2. Infants who will be presenting to the clinic for their second Diphtheria, Pertussis, Tetanus (DPT) and second Oral Polio Vaccine (OPV) immunisations and are aged less than one
Exclusion criteria
Exclusion criteria: 1. Infants with known hypersensitivity to study drugs 2. Infants with congenital malformations and history of haemolytic anaemia 3. Infants with a history of blood transfusion in the previous week 4. SP treatment in the previous two weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Effectiveness of intermittent malaria treatment of infants with SP (versus placebo) within the Kenya EPI schedule in preventing severe anaemia and malaria 2. Assessment of serological responses to EPI vaccines in children receiving SP versus those receiving placebo for SP | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Determine whether intermittent malaria treatment results in a rebound effect of more episodes of malaria after treatment is stopped 2. Determine whether intermittent malaria treatment results in improved growth of infants | — |
Countries
Kenya
Outcome results
None listed